Viper antivenom
- Generic Name
- Viper antivenom
- Brand Names
- Anavip
- Drug Type
- Biotech
- Unique Ingredient Identifier
- 92VV7G83ED
Overview
Viper antivenom consists of antibodies derived from horses immunized and subsequently developed antibodies against snake venoms. ANAVIP, an equine-derived antivenom made with venom from Bothrops asper and Crotalus durissus, was first approved by the FDA on October 1, 2015, for the management of North American rattlesnake envenomation.
Background
Viper antivenom consists of antibodies derived from horses immunized and subsequently developed antibodies against snake venoms. ANAVIP, an equine-derived antivenom made with venom from Bothrops asper and Crotalus durissus, was first approved by the FDA on October 1, 2015, for the management of North American rattlesnake envenomation.
Indication
Equine-derived viper antivenom is indicated for the management of adult and pediatric patients with North American Pit Viper envenomation.
Associated Conditions
- American rattlesnake envenomation
Clinical Trials
FDA Approved Products
Singapore Approved Products
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.